Replies to post #414613 on Anavex Life Sciences Corp (AVXL)

[bas2020]

You got that backwards...

SAVA has been brave enough to include moderate AD patients in its trials whereas AVXL included more healthy patients.

Anavex had more advanced-stage patients overall. Go check the MMSE scores again.

[georgejjl]

The facts are that SAVA wishes that they had only recruited mild participants rather than a mixture of mild and moderate Alzheimer's participants.

In the new release, Cassava noted the total scores declined by 0.5 points across all patients. That likely hammered SAVA stock.

Mixed Results In Mild, Moderate Groups

It's important to note, the results were mixed between mild and moderate patients. Scores of symptoms improved by 2.4 points in mild patients. In moderate patients, the scores worsened by 4.4 points.

https://www.investors.com/news/technology/sava-stock-plummets-as-highly-desirable-results-do-not-pass-muster-with-investors/

The truth is that they had not learned from previous trials.

Anavex Life Sciences, Biogen and Eisai have learned from previous trials.

GOD bless,